Aarhus University Seal / Aarhus Universitets segl

Succes Stories

Methyl Detect

Methyl Detect ApS was founded in 2016 with the intent to make cost-effective gene specific DNA methylation assays based upon MS-HRM technique available for researchers.

The company is based on an invention made at the Department of Biomedicine relating to a an optimised strategy for PCR primer design, that allow for more sensive methylation detection than what was previously possible.

The Technology Transfer Office invested in a patent application and supported the inventors in creating a company to further develop the technology.

MethylDetect

RadiSurf

RadiSurf was established in 2015.

The goal of the Company is to provide new solutions for adhesion, based on their knowledge regarding Surface chemistry.

The technology is ideal for a wide range of applications such as medico and Electronics.

RadiSurf

VPCIR.COM

VPCIR.COM is a new company focussing on food safety.

The Company is developing a patent pending technology for detection of food pathogens.

They are a spin-out from Aarhus University and The Chines University of Hong Kong.

 

VPCIR.COM

VisBlue

VisBlue was founded in 2014 order to commercializes green energy storage with a patented vanadium redox flow battery.

The company is based on an invention made at the Department of Engineering relating to a system coupling a solar cell to a Redox Flow Battery.

The Technology Transfer Office invested in a patent application and supported the inventors in creating a company to further develop the technology.

Visblue

STipe Therapeutics

STipe Therapeutics is a spin-out from Aarhus University founded in 2018. The company has developed First-in-Class drugs that exploits and strengthens the STING pathway response to combat cancer, by increasing the innate immune response within the tumor microenvironment. STipe received €20 mio in funding in September.

STipe Therapeutics

Draupnir Bio

Draupnir Bio is a spin-out from Department of Biomedicine at Aarhus University. The company's lead program focuses on the development of glycan mimetics for treatment of cardiovascular diseases. In October Draupnir Bio received €30 mio. in Funding.

More spin-outs

To see examples of our spin-outs, please follow this link.